506 research outputs found
Applications and Challenges of Real-time Mobile DNA Analysis
The DNA sequencing is the process of identifying the exact order of
nucleotides within a given DNA molecule. The new portable and relatively
inexpensive DNA sequencers, such as Oxford Nanopore MinION, have the potential
to move DNA sequencing outside of laboratory, leading to faster and more
accessible DNA-based diagnostics. However, portable DNA sequencing and analysis
are challenging for mobile systems, owing to high data throughputs and
computationally intensive processing performed in environments with unreliable
connectivity and power.
In this paper, we provide an analysis of the challenges that mobile systems
and mobile computing must address to maximize the potential of portable DNA
sequencing, and in situ DNA analysis. We explain the DNA sequencing process and
highlight the main differences between traditional and portable DNA sequencing
in the context of the actual and envisioned applications. We look at the
identified challenges from the perspective of both algorithms and systems
design, showing the need for careful co-design
Enabling Automated, Rich, and Versatile Data Management for Android Apps with BlueMountain
Abstract Today's mobile apps often leverage cloud services to manage their own data as well as user data, enabling many desired features such as backup and sharing. However, this comes at a cost; developers have to manually craft their logic and potentially repeat a similar process for different cloud providers. In addition, users are restricted to the design choices made by developers; for example, once a developer releases an app that uses a particular cloud service, it is impossible for a user to later customize the app and choose a different service. In this paper, we explore the design space of an app instrumentation tool that automatically integrates cloud storage services for Android apps. Our goal is to allow developers to treat all storage operations as local operations, and automatically enable cloud features customized for individual needs of users and developers. We discuss various scenarios that can benefit from such an automated tool, challenges associated with the development of it, and our ideas to address these challenges
Ultrathin compound semiconductor on insulator layers for high performance nanoscale transistors
Over the past several years, the inherent scaling limitations of electron
devices have fueled the exploration of high carrier mobility semiconductors as
a Si replacement to further enhance the device performance. In particular,
compound semiconductors heterogeneously integrated on Si substrates have been
actively studied, combining the high mobility of III-V semiconductors and the
well-established, low cost processing of Si technology. This integration,
however, presents significant challenges. Conventionally, heteroepitaxial
growth of complex multilayers on Si has been explored. Besides complexity, high
defect densities and junction leakage currents present limitations in the
approach. Motivated by this challenge, here we utilize an epitaxial transfer
method for the integration of ultrathin layers of single-crystalline InAs on
Si/SiO2 substrates. As a parallel to silicon-on-insulator (SOI) technology14,we
use the abbreviation "XOI" to represent our compound semiconductor-on-insulator
platform. Through experiments and simulation, the electrical properties of InAs
XOI transistors are explored, elucidating the critical role of quantum
confinement in the transport properties of ultrathin XOI layers. Importantly, a
high quality InAs/dielectric interface is obtained by the use of a novel
thermally grown interfacial InAsOx layer (~1 nm thick). The fabricated FETs
exhibit an impressive peak transconductance of ~1.6 mS/{\mu}m at VDS=0.5V with
ON/OFF current ratio of greater than 10,000 and a subthreshold swing of 107-150
mV/decade for a channel length of ~0.5 {\mu}m
Strong coupling, discrete symmetry and flavour
We show how two principles - strong coupling and discrete symmetry - can work
together to generate the flavour structure of the Standard Model. We propose
that in the UV the full theory has a discrete flavour symmetry, typically only
associated with tribimaximal mixing in the neutrino sector. Hierarchies in the
particle masses and mixing matrices then emerge from multiple strongly coupled
sectors that break this symmetry. This allows for a realistic flavour
structure, even in models built around an underlying grand unified theory. We
use two different techniques to understand the strongly coupled physics:
confinement in N=1 supersymmetry and the AdS/CFT correspondence. Both
approaches yield equivalent results and can be represented in a clear,
graphical way where the flavour symmetry is realised geometrically.Comment: 31 pages, 5 figures, updated references and figure
Estimating the Impact of Adding C-Reactive Protein as a Criterion for Lipid Lowering Treatment in the United States
BACKGROUND: There is growing interest in using C-reactive protein (CRP) levels to help select patients for lipid lowering therapyβalthough this practice is not yet supported by evidence of benefit in a randomized trial. OBJECTIVE: To estimate the number of Americans potentially affected if a CRP criteria were adopted as an additional indication for lipid lowering therapy. To provide context, we also determined how well current lipid lowering guidelines are being implemented. METHODS: We analyzed nationally representative data to determine how many Americans age 35 and older meet current National Cholesterol Education Program (NCEP) treatment criteria (a combination of risk factors and their Framingham risk score). We then determined how many of the remaining individuals would meet criteria for treatment using 2 different CRP-based strategies: (1) narrow: treat individuals at intermediate risk (i.e., 2 or more risk factors and an estimated 10β20% risk of coronary artery disease over the next 10Β years) with CRPβ>β3Β mg/L and (2) broad: treat all individuals with CRPβ>β3Β mg/L. DATA SOURCE: Analyses are based on the 2,778 individuals participating in the 1999β2002 National Health and Nutrition Examination Survey with complete data on cardiac risk factors, fasting lipid levels, CRP, and use of lipid lowering agents. MAIN MEASURES: The estimated number and proportion of American adults meeting NCEP criteria who take lipid-lowering drugs, and the additional number who would be eligible based on CRP testing. RESULTS: About 53 of the 153 million Americans aged 35 and older meet current NCEP criteria (that do not involve CRP) for lipid-lowering treatment. Sixty-five percent, however, are not currently being treated, even among those at highest risk (i.e., patients with established heart disease or its risk equivalent)β62% are untreated. Adopting the narrow and broad CRP strategies would make an additional 2.1 and 25.3 million Americans eligible for treatment, respectively. The latter strategy would make over half the adults age 35 and older eligible for lipid-lowering therapy, with most of the additionally eligible (57%) coming from the lowest NCEP heart risk category (i.e., 0β1 risk factors). CONCLUSION: There is substantial underuse of lipid lowering therapy for American adults at high risk for coronary disease. Rather than adopting CRP-based strategies, which would make millions more lower risk patients eligible for treatment (and for whom treatment benefit has not yet been demonstrated in a randomized trial), we should ensure the treatment of currently defined high-risk patients for whom the benefit of therapy is established
The genomes of two key bumblebee species with primitive eusocial organization
Background: The shift from solitary to social behavior is one of the major evolutionary transitions. Primitively eusocial bumblebees are uniquely placed to illuminate the evolution of highly eusocial insect societies. Bumblebees are also invaluable natural and agricultural pollinators, and there is widespread concern over recent population declines in some species. High-quality genomic data will inform key aspects of bumblebee biology, including susceptibility to implicated population viability threats. Results: We report the high quality draft genome sequences of Bombus terrestris and Bombus impatiens, two ecologically dominant bumblebees and widely utilized study species. Comparing these new genomes to those of the highly eusocial honeybee Apis mellifera and other Hymenoptera, we identify deeply conserved similarities, as well as novelties key to the biology of these organisms. Some honeybee genome features thought to underpin advanced eusociality are also present in bumblebees, indicating an earlier evolution in the bee lineage. Xenobiotic detoxification and immune genes are similarly depauperate in bumblebees and honeybees, and multiple categories of genes linked to social organization, including development and behavior, show high conservation. Key differences identified include a bias in bumblebee chemoreception towards gustation from olfaction, and striking differences in microRNAs, potentially responsible for gene regulation underlying social and other traits. Conclusions: These two bumblebee genomes provide a foundation for post-genomic research on these key pollinators and insect societies. Overall, gene repertoires suggest that the route to advanced eusociality in bees was mediated by many small changes in many genes and processes, and not by notable expansion or depauperation
Circulating CD133+CD34+ progenitor cells inversely correlate with soluble ICAM-1 in early ischemic stroke patients
<p>Abstract</p> <p>Background and Purpose</p> <p>Both endothelial progenitor cells (EPC) and markers of neuroinflammation are candidate biomarkers for stroke severity and outcome prediction. A relationship between EPC and neuroinflammatory markers in early stroke is not fully elucidated. The objectives were to investigate correlations between EPC and neuroinflammation markers (adhesion molecules ICAM-1, VCAM-1, E-selectin, tumor necrosis factor (TNF)-Ξ±, interleukin (IL)-6, endothelin (ET)-1, markers of tissue injury (matrix metalloproteinases (MMP)-9 and tissue inhibitor of matrix metalloproteinases (TIMP)-1) in early stroke patients.</p> <p>Methods</p> <p>We prospectively recruited symptomatic patients with ischemic cerebrovascular disease. We assessed stroke severity by using of acute (diffusion-weighted imaging (DWI) and final lesion volumes (fluid attenuated inversion recovery (FLAIR). We measured serum soluble ICAM-1, VCAM-1, E-selectin, MMP-9, TIMP-1 and plasma TNF-Ξ±, IL-6, ET-1 by ELISA, and quantified EPC in mononuclear fraction of peripheral blood on days 1 and 3 in 17 patients (mean(SD) age 62(14), with admission National Institutes of Health Stroke Scale (NIHSS) 10(8)) selected from 175 patients with imaging confirmed ischemic stroke. Non-parametric statistics, univariate and multivariate analysis were used.</p> <p>Results</p> <p>Only ICAM-1 inversely correlated with EPC subset CD133+CD34+ on day 1 (Spearman r = -0.6, p < 0.01) and on day 3 (r = -0.967, p < 0.001). This correlation remained significant after adjustment for age and NIHSS (beta -0.992, p < 0.004), for glucose and systolic blood pressure (beta -0.86, p < 0.005), and for white blood cells and hematocrit (beta -1.057, p < 0.0001) on day 3. MMP-9 (r = 0.509, p < 0.04) and MMP-9/TIMP-1 (r = 0.59, p < 0.013) on day 1 correlated with acute lesion volume. Both IL-6 (r = 0.624, p < 0.01) and MMP-9/TIMP-1 (r = 0.56, p < 0.02) correlated with admission NIHSS.</p> <p>Conclusion</p> <p>Our study showed that high ICAM-1 is associated with low CD133+CD34+subset of EPC. Biomarkers of neuroinflammation may predict tissue injury and stroke severity in early ischemia.</p
TET1 is a tumor suppressor of hematopoietic malignancy
The methylcytosine dioxygenase TET1 (βten-eleven translocation 1β) is an important regulator of 5-hydroxymethylcytosine (5hmC) in embryonic stem cells. The diminished expression of TET proteins and loss of 5hmC in many tumors suggests a critical role for the maintenance of this epigenetic modification. Here we found that deletion of Tet1 promoted the development of B cell lymphoma in mice. TET1 was required for maintenance of the normal abundance and distribution of 5hmC, which prevented hypermethylation of DNA, and for regulation of the B cell lineage and of genes encoding molecules involved in chromosome maintenance and DNA repair. Whole-exome sequencing of TET1-deficient tumors revealed mutations frequently found in non-Hodgkin B cell lymphoma (B-NHL), in which TET1 was hypermethylated and transcriptionally silenced. Our findings provide in vivo evidence of a function for TET1 as a tumor suppressor of hematopoietic malignancy.National Institutes of Health (U.S.) (5RO1HD045022)National Institutes of Health (U.S.) (5R37CA084198
Chronic Cyclodextrin Treatment of Murine Niemann-Pick C Disease Ameliorates Neuronal Cholesterol and Glycosphingolipid Storage and Disease Progression
BACKGROUND:Niemann-Pick type C (NPC) disease is a fatal neurodegenerative disorder caused most commonly by a defect in the NPC1 protein and characterized by widespread intracellular accumulation of unesterified cholesterol and glycosphingolipids (GSLs). While current treatment therapies are limited, a few drugs tested in Npc1(-/-) mice have shown partial benefit. During a combination treatment trial using two such compounds, N-butyldeoxynojirimycin (NB-DNJ) and allopregnanolone, we noted increased lifespan for Npc1(-/-) mice receiving only 2-hydroxypropyl-beta-cyclodextrin (CD), the vehicle for allopregnanolone. This finding suggested that administration of CD alone, but with greater frequency, might provide additional benefit. METHODOLOGY/PRINCIPAL FINDINGS:Administration of CD to Npc1(-/-) mice beginning at either P7 or P21 and continuing every other day delayed clinical onset, reduced intraneuronal cholesterol and GSL storage as well as free sphingosine accumulation, reduced markers of neurodegeneration, and led to longer survival than any previous treatment regime. We reasoned that other lysosomal diseases characterized by cholesterol and GSL accumulation, including NPC disease due to NPC2 deficiency, GM1 gangliosidosis and mucopolysaccharidosis (MPS) type IIIA, might likewise benefit from CD treatment. Treated Npc2(-/-) mice showed benefits similar to NPC1 disease, however, mice with GM1 gangliosidosis or MPS IIIA failed to show reduction in storage. CONCLUSIONS/SIGNIFICANCE:Treatment with CD delayed clinical disease onset, reduced intraneuronal storage and secondary markers of neurodegeneration, and significantly increased lifespan of both Npc1(-/-) and Npc2(-/-) mice. In contrast, CD failed to ameliorate cholesterol or glycosphingolipid storage in GM1 gangliosidosis and MPS IIIA disease. Understanding the mechanism(s) by which CD leads to reduced neuronal storage may provide important new opportunities for treatment of NPC and related neurodegenerative diseases characterized by cholesterol dyshomeostasis
- β¦